Blocking pathways and reducing overexpression of oncogenes
Hi everyone, Iām just sharing questions I have for my oncologist as heās a colorectal cancer researcher. Iāll report back on Jan 6 after my appointment with him. Iām not asking questions to the group - I just canāt be fucked changing it to statements because itās 35 degrees today, feels like 40 degrees and Iām dying š¤£. Hopefully if you have the same risk factors, this could help guide further research. Also, a 10 year HBOT study shows if you do it before and after radiation, side effects were reduced or non-existent in 80% of participants (rectal cancer). Itās only subsided for brain cancer patients in Australia and the TGA are cunts here. But if you can get a subsidy, go for it! It also reduces drug resistance and can improve chemo efficacy. Questions: Have you had any patients on Rapamycin? I have been looking into this and believe there are early stage clinical trials going on for its use in drug resistant colorectal cancer and specifically its synergistic effects with 5-FU, e.g. inhibits mTOR, increases senescence, decreases thymidylate syntheses and angiogenesis etc. Have you ever used or researched inhibitors of ABCG2 pumps to reverse MDR1 over-expression? I noticed the cells in the length of my tumour decreased (assuming these are the neoplasmic cells sensitive to capecitabine) but the width snd height have grown quickly, so perhaps these are the more resistant populations. What is the best way to target VEGF and ANG overexpressions? These are the highest risk factors for angiogenesis that came up on my Onconomics testing, along with FGF, PDGF, and ANG1 and 2. Vabysmo looks promising but can impact eye health. Have you ever used Avastin as an adjunct outside of its use along side other immunotherapy drugs to block VEGF? I have 35% sensitivity to this and thereās promising data when used with chemo or metabolic therapy and HBOT, but Keytruda, Opdivo and Yervoy were completely useless for me because I have normal expression of MMR genes and no MMR deficiency.